Skip to main content

NASDAQ:SRNE - Sorrento Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $28.75
  • Forecasted Upside: 334.29 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$6.62
▲ +0.27 (4.25%)
1 month | 3 months | 12 months
Get New Sorrento Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SRNE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SRNE

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$28.75
▲ +334.29% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Sorrento Therapeutics in the last 3 months. The average price target is $28.75, with a high forecast of $35.00 and a low forecast of $24.00. The average price target represents a 334.29% upside from the last price of $6.62.

Buy

The current consensus among 4 investment analysts is to buy stock in Sorrento Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/21/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/19/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/17/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/15/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/16/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/29/2021B. RileyInitiated CoverageBuy$26.00High
i
Rating by M. Mamtani at B. Riley
1/21/2021Alliance Global PartnersInitiated CoverageBuy$35.00Medium
i
7/31/2020HC WainwrightBoost Price TargetBuy$24.00 ➝ $30.00High
i
Rating by Ram Selvaraju at HC Wainwright
7/6/2020HC WainwrightReiterated RatingBuy$24.00High
i
Rating by Ram Selvaraju at HC Wainwright
6/11/2020HC WainwrightReiterated RatingBuy$24.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
5/26/2020Dawson JamesInitiated CoverageBuy ➝ Buy$24.00Low
i
5/26/2020HC WainwrightReiterated RatingBuy$24.00Low
i
Rating by Ram Selvaraju at HC Wainwright
5/18/2020HC WainwrightReiterated RatingBuy$24.00High
i
3/30/2020HC WainwrightLower Price TargetBuy$28.00 ➝ $24.00High
i
10/7/2019JMP SecuritiesInitiated CoverageOutperform$21.00High
i
8/12/2019HC WainwrightReiterated RatingBuy$30.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
7/23/2019HC WainwrightLower Price TargetBuy$40.00 ➝ $30.00High
i
Rating by Ram Selvaraju at HC Wainwright
4/17/2019HC WainwrightSet Price TargetBuy$40.00Low
i
Rating by Ram Selvaraju at HC Wainwright
3/22/2019HC WainwrightSet Price TargetBuy$40.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
3/20/2019B. RileyBoost Price TargetBuy ➝ Buy$10.50 ➝ $12.00High
i
1/23/2019HC WainwrightSet Price TargetBuy$40.00High
i
Rating by Ram Selvaraju at HC Wainwright
12/20/2018HC WainwrightSet Price TargetBuy$20.00Low
i
Rating by Ram Selvaraju at HC Wainwright
12/12/2018HC WainwrightSet Price TargetBuy$40.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
11/12/2018OppenheimerSet Price TargetBuy$10.00Medium
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
10/9/2018HC WainwrightSet Price TargetBuy$40.00Low
i
Rating by Ram Selvaraju at HC Wainwright
9/20/2018HC WainwrightReiterated RatingBuy$40.00Low
i
Rating by Ram Selvaraju at HC Wainwright
9/10/2018HC WainwrightSet Price TargetBuy$40.00Low
i
Rating by Ram Selvaraju at HC Wainwright
8/29/2018HC WainwrightSet Price TargetBuy$40.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
8/13/2018HC WainwrightReiterated RatingBuy$40.00Low
i
Rating by Ram Selvaraju at HC Wainwright
7/6/2018HC WainwrightSet Price TargetBuy$40.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
6/28/2018B. RileyInitiated CoverageBuy$14.25Medium
i
Rating by A. D'silva at B. Riley
6/11/2018HC WainwrightReiterated RatingBuy$40.00High
i
Rating by Ram Selvaraju at HC Wainwright
5/14/2018HC WainwrightSet Price TargetBuy$40.00Low
i
Rating by Ram Selvaraju at HC Wainwright
5/4/2018HC WainwrightSet Price TargetBuy$40.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
4/12/2018HC WainwrightSet Price TargetBuy$40.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
4/3/2018HC WainwrightBoost Price TargetBuy ➝ Buy$38.00 ➝ $40.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
3/6/2018HC WainwrightSet Price TargetBuy$38.00High
i
Rating by Ram Selvaraju at HC Wainwright
2/28/2018HC WainwrightBoost Price TargetBuy$35.00 ➝ $38.00High
i
Rating by Ram Selvaraju at HC Wainwright
2/1/2018HC WainwrightReiterated RatingBuy$30.00Low
i
Rating by Ram Selvaraju at HC Wainwright
1/23/2018HC WainwrightSet Price TargetBuy$30.00Low
i
Rating by Ram Selvaraju at HC Wainwright
1/19/2018OppenheimerReiterated RatingBuy$9.00High
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
1/16/2018HC WainwrightReiterated RatingBuy$20.00 ➝ $30.00High
i
Rating by R. Selvaraju at HC Wainwright
11/15/2017OppenheimerSet Price TargetBuy$7.00 ➝ $6.00N/A
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
10/5/2017HC WainwrightReiterated RatingBuy$20.00N/A
i
Rating by R. Selvaraju at HC Wainwright
9/18/2017HC WainwrightReiterated RatingBuy$20.00High
i
Rating by R. Selvaraju at HC Wainwright
8/30/2017HC WainwrightSet Price TargetBuy$20.00High
i
Rating by Ram Selvaraju at HC Wainwright
8/29/2017OppenheimerSet Price TargetBuy$7.00High
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
8/24/2017HC WainwrightReiterated RatingBuy$20.00Low
i
Rating by Ram Selvaraju at HC Wainwright
8/22/2017OppenheimerSet Price TargetBuy$7.00High
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
8/10/2017OppenheimerSet Price TargetBuy$7.00Low
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
8/4/2017OppenheimerInitiated CoverageOutperform$7.00Low
i
8/3/2017Roth CapitalInitiated CoverageBuy$7.00High
i
Rating by Mark Breidenbach at Roth Capital
8/3/2017UBS GroupInitiated CoverageOutperform$7.00High
i
7/4/2017HC WainwrightSet Price TargetBuy$20.00High
i
Rating by Ram Selvaraju at HC Wainwright
6/27/2017HC WainwrightSet Price TargetBuy$20.00N/A
i
Rating by Ram Selvaraju at HC Wainwright
6/17/2017(FBRC)Reiterated RatingBuyLow
i
Rating by Edward White at (FBRC)
6/15/2017HC WainwrightSet Price TargetBuy$20.00High
i
Rating by Ram Selvaraju at HC Wainwright
5/22/2017HC WainwrightSet Price TargetBuy$20.00High
i
Rating by Ram Selvaraju at HC Wainwright
5/22/2017Rodman & RenshawLower Price TargetBuy ➝ Buy$30.00 ➝ $20.00High
i
5/22/2017(FBRC)Reiterated RatingOutperform ➝ Outperform$13.00 ➝ $9.00High
i
Rating by Edward White at (FBRC)
4/4/2017(FBRC)Reiterated RatingBuyHigh
i
Rating by Edward White at (FBRC)
1/12/2017(FBRC)Set Price TargetBuy$15.00N/A
i
Rating by Edward White at (FBRC)
12/2/2016(FBRC)Reiterated RatingBuyN/A
i
11/2/2016Roth CapitalSet Price TargetBuy$15.00N/A
i
Rating by Joseph Pantginis at Roth Capital
10/3/2016Roth CapitalInitiated CoverageBuy$15.00N/A
i
Rating by J. Pantginis at Roth Capital
8/12/2016Brean CapitalReiterated RatingBuyN/A
i
Rating by Difei Yang at Brean Capital
8/4/2016(FBRC)Reiterated RatingBuyN/A
i
Rating by Edward White at (FBRC)
7/17/2016Rodman & RenshawReiterated RatingBuyN/A
i
Rating by Ram Selvaraju at Rodman & Renshaw
7/15/2016Brean CapitalReiterated RatingBuy$15.00N/A
i
Rating by Difei Yang at Brean Capital
7/11/2016Rodman & RenshawReiterated RatingBuyN/A
i
Rating by Ram Selvaraju at Rodman & Renshaw
6/8/2016Rodman & RenshawReiterated RatingBuyN/A
i
Rating by Ram Selvaraju at Rodman & Renshaw
(Data available from 5/16/2016 forward)
Sorrento Therapeutics logo
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches; and Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host diseases. The company also develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. In addition, it engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. Additionally, the company has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; and Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.
Read More

Today's Range

Now: $6.62
$6.31
$6.72

50 Day Range

MA: $7.70
$6.35
$8.81

52 Week Range

Now: $6.62
$3.82
$19.39

Volume

4,836,071 shs

Average Volume

13,796,022 shs

Market Capitalization

$1.90 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.7

Frequently Asked Questions

What sell-side analysts currently cover shares of Sorrento Therapeutics?

The following Wall Street analysts have issued stock ratings on Sorrento Therapeutics in the last year: Alliance Global Partners, B. Riley, Dawson James, HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for SRNE.

What is the current price target for Sorrento Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Sorrento Therapeutics in the last year. Their average twelve-month price target is $28.75, suggesting a possible upside of 334.3%. Alliance Global Partners has the highest price target set, predicting SRNE will reach $35.00 in the next twelve months. Dawson James has the lowest price target set, forecasting a price of $24.00 for Sorrento Therapeutics in the next year.
View the latest price targets for SRNE.

What is the current consensus analyst rating for Sorrento Therapeutics?

Sorrento Therapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SRNE will outperform the market and that investors should add to their positions of Sorrento Therapeutics.
View the latest ratings for SRNE.

What other companies compete with Sorrento Therapeutics?

How do I contact Sorrento Therapeutics' investor relations team?

Sorrento Therapeutics' physical mailing address is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. The biopharmaceutical company's listed phone number is 858-203-4100 and its investor relations email address is [email protected] The official website for Sorrento Therapeutics is www.sorrentotherapeutics.com.